Cat. No.: HY-100675

JTE-013

Name: JTE-013
Brand: MedChemExpress
SKU: HY-100675
Price: 88.00 USD
Availability: InStock
Rating: 5 (12 reviews)

12 Cited Publications

Customer Review

Based on 12 publication(s) in Google Scholar

JTE-013 is a potent and specific S1P₂ (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P₂ with IC₅₀s of 17 nM and 22 nM, respectively.

For research use only. We do not sell to patients.

Purity : 99.57%
CAS No.: 383150-41-2
Formula: C₁₇H₁₉Cl₂N₇O
Molecular Weight:408.29

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

JTE-013 Chemical Structure

CAS No.: 383150-41-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (12)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 17 nM (S1P₂ for human) and 22 nM (S1P₂ for rat)^[1]

All LPL Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	16.45 μM Compound: JTE-013	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	5.97 μM Compound: JTE-013	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
HCT-116	EC₅₀	17.13 μM Compound: JTE-013	Reversal of 5-FU resistance against human HCT-116 cells overexpressing DPD assessed as inhibition of cell proliferation measured after 72 hrs in presence of 5-FU by MTT assay Reversal of 5-FU resistance against human HCT-116 cells overexpressing DPD assessed as inhibition of cell proliferation measured after 72 hrs in presence of 5-FU by MTT assay	[PMID: 34411894]
HCT-116	EC₅₀	18.28 μM Compound: JTE-013	Reversal of 5-FU resistance against 5-FU resistant DPD expressed human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs in presence of 5-FU by MTT assay Reversal of 5-FU resistance against 5-FU resistant DPD expressed human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs in presence of 5-FU by MTT assay	[PMID: 34688013]
NCM460	EC₅₀	61.34 μM Compound: JTE-013	Cytotoxicity against human NCM460 cells assessed as cell viability measured after 72 hrs in presence of 5-FU by MTT assay Cytotoxicity against human NCM460 cells assessed as cell viability measured after 72 hrs in presence of 5-FU by MTT assay	[PMID: 34411894]
SW620/5-FU	EC₅₀	58.58 μM Compound: JTE-013	Reversal of 5-FU resistance against human SW620/5-FU cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of 5-FU by MTT assay Reversal of 5-FU resistance against human SW620/5-FU cells assessed as inhibition of cell proliferation measured after 72 hrs in presence of 5-FU by MTT assay	[PMID: 34411894]
SW620/5-FU	EC₅₀	58.58 μM Compound: JTE-013	Reversal of 5-FU resistance against human SW620/5-FU cells assessed as reduction in cell viability incubated for 48 hrs in presence of 5-FU by MTT assay Reversal of 5-FU resistance against human SW620/5-FU cells assessed as reduction in cell viability incubated for 48 hrs in presence of 5-FU by MTT assay	[PMID: 34688013]

In Vitro

JTE-013 (50-200 μM; 1-3 days) reduces cell viability^[1].
JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation^[1].
JTE-013 displays 4.2% inhibition of S1P₃ and does not antagonize S1P₁ at concentrations up to 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

SK-N-AS cells
Concentration:

50, 100, 150, 200 μM
Incubation Time:

1-3 days
Result:

Reduced cell viability.

Western Blot Analysis^[1]

Cell Line:

SK-N-AS cells
Concentration:

10, 100, 1000 nM
Incubation Time:

30 mins
Result:

Reversed S1P-induced Akt inhibition and inhibited S1P-induced ERK activation.

In Vivo

JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Six-week-old female athymic NCr-nu/nu nude mice^[1]
Dosage:

30 mg/kg
Administration:

Gavage; daily for 14 consecutive days
Result:

Reduced tumor size and tumor weight.

Chemical Information

CAS No. 383150-41-2
Appearance Solid
Molecular Weight 408.29
Formula C₁₇H₁₉Cl₂N₇O
Color White to off-white
SMILES

CC(C1=C2C(N(C)N=C2C)=NC(NNC(NC3=CC(Cl)=NC(Cl)=C3)=O)=C1)C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (12)

All In Vivo Efficacy StudyWBBio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis. [Abstract]

2025 Jul 16. PMID: 40665874
Autophagy

Mitophagy-mediated S1P facilitates muscle adaptive responses to endurance exercise through SPHK1-S1PR1/S1PR2 in slow-twitch myofibers. [Abstract]

2025 Apr 3. PMID: 40181214

JTE-013 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]

8-week-old male C57BL/6J mice were subjected to 6-week treadmill training and treated with intraperitoneal injections of vehicle (4 mg/mL BSA in normal saline), W146 (5 mg/kg, every other day), JTE-013 (5 mg/kg, every other day) or CAY10444 (5 mg/kg, every other day) for 6 weeks. Running population, running time, distance and work performed until exhaustion during treadmill stress test (n = 6).

JTE-013 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]

8-week-old male C57BL/6J mice were subjected to 6-week treadmill training and treated with intraperitoneal injections of vehicle (4 mg/mL BSA in normal saline), W146 (5 mg/kg, every other day), JTE-013 (5 mg/kg, every other day) or CAY10444 (5 mg/kg, every other day) for 6 weeks. Protein levels of OXPHOS complexes in slow-twitch muscles (sol) (n = 4).

JTE-013 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]

PPARGC1A protein levels in C2C12 myotubes treated with 10 μM JTE-013 for 48 h after the stimulation of 10 μM FCCP (n = 4).

JTE-013 purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]

Mitochondrial turnover ratio of C2C12 myotubes treated with 10 μM JTE-013, 5 μM W146 or 10 μM CAY10444 for 48 h after the stimulation of 10 μM FCCP (n = 3).
Nat Commun

Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy. [Abstract]

2023 Mar 9;14(1):1305. PMID: 36894566
J Control Release

Fibrotic collagen-targeted delivery system blocks pancreatic intercellular crosstalk to alleviate pancreatic fibrosis. [Abstract]

2025 Oct 6;388(Pt 1):114278. PMID: 41045968
Cell Commun Signal

Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]

2024 Aug 7;22(1):391. PMID: 39113090
Phytomedicine

Alisol A 24-acetate protects against NASH-associated fibrosis via suppression of Kupffer cell-derived SPHK1/S1P axis. [Abstract]

2025 Sep 19:148:157271. PMID: 40992063
Br J Pharmacol

2026 Jul 14. PMID: 42448629
Br J Pharmacol

Inhibition of sphingosine-1-phosphate receptor-2 attenuates chronic gastritis via blocking nuclear translocation of S1P2 receptors in epithelial cells. [Abstract]

2025 Dec 30. PMID: 41472315
PeerJ

Reversal of cholestatic liver disease by the inhibition of sphingosine 1-phosphate receptor 2 signaling. [Abstract]

2024 Jan 16:12:e16744. PMID: 38250717
Discov Oncol

Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway. [Abstract]

2023 Jan 11;14(1):4. PMID: 36631680

JTE-013 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 Jan 11;14(1):4. [Abstract]

JTE-013 (0, 24, and 48 h) significantly inhibits the growth rate of Huh7 and HepG2 cells.

JTE-013 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 Jan 11;14(1):4. [Abstract]

JTE-013 significantly inhibits the proliferation ability of HCC cells.

JTE-013 purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 Jan 11;14(1):4. [Abstract]

JTE-013 significantly inhibits the proliferation and invasive ability of HCC cells.
Exp Ther Med

SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway. [Abstract]

2018 Jun;15(6):5007-5016. PMID: 29805524
bioRxiv

2026 Sep 22.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (244.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4492 mL

12.2462 mL

24.4924 mL

5 mM

0.4898 mL

2.4492 mL

4.8985 mL

10 mM

0.2449 mL

1.2246 mL

2.4492 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li MH, et al. Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. J Pharmacol Exp Ther. 2015 Sep;354(3):261-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4492 mL	12.2462 mL	24.4924 mL	61.2310 mL
	5 mM	0.4898 mL	2.4492 mL	4.8985 mL	12.2462 mL
	10 mM	0.2449 mL	1.2246 mL	2.4492 mL	6.1231 mL
	15 mM	0.1633 mL	0.8164 mL	1.6328 mL	4.0821 mL
	20 mM	0.1225 mL	0.6123 mL	1.2246 mL	3.0615 mL
	25 mM	0.0980 mL	0.4898 mL	0.9797 mL	2.4492 mL
	30 mM	0.0816 mL	0.4082 mL	0.8164 mL	2.0410 mL
	40 mM	0.0612 mL	0.3062 mL	0.6123 mL	1.5308 mL
	50 mM	0.0490 mL	0.2449 mL	0.4898 mL	1.2246 mL
	60 mM	0.0408 mL	0.2041 mL	0.4082 mL	1.0205 mL
	80 mM	0.0306 mL	0.1531 mL	0.3062 mL	0.7654 mL
	100 mM	0.0245 mL	0.1225 mL	0.2449 mL	0.6123 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

JTE-013

Publications Citing Use of MedChemExpress (MCE) JTE-013

All LPL Receptor Isoforms